N-desmethyl Enzalutamide is primarily used in the field of oncology, particularly in the treatment of prostate cancer. It functions as an active metabolite of Enzalutamide, which is a well-known androgen receptor inhibitor. By binding to androgen receptors, it effectively blocks the action of androgens, such as testosterone, which are known to promote the growth of prostate cancer cells. This makes it a valuable component in therapeutic strategies aimed at managing castration-resistant prostate cancer (CRPC). Additionally, its role in research and development is significant, as it helps in understanding the pharmacokinetics and pharmacodynamics of Enzalutamide, aiding in the optimization of dosing regimens and the development of more effective treatment protocols.